sabizabulin in men with mcrpc who progressed on an androgen receptor targeting agent
Published 2 years ago • 163 plays • Length 0:58Download video MP4
Download video MP3
Similar videos
-
0:56
phase i/ii trial of bms-986365 in mcrpc resistant to arpis
-
1:28
vision: 177lu-psma-617 in psma-positive mcrpc
-
1:07
initial results from phase i/ii study of arv-766 in mcrpc
-
3:06
sabizabulin – mechanism of action against prostate cancer
-
0:35
the potential role of arv-766, an oral protac ar degrader, in mcrpc
-
6:01
androgen receptor and castration-resistant prostate cancer
-
8:09
treating mcrpc with newer hormonal agents
-
1:47
dr. george on investigational agents downstream of the androgen receptor in prostate cancer
-
13:04
androgen receptor-targeted ttherapies in advanced prostate cancer
-
4:41
how the landscape of treating crpc has evolved with the introduction of targeted treatment
-
28:19
targeting ar in castration resistant prostate cancer
-
9:33
the transformer study: bipolar androgen therapy vs enzalutamide in asymptomatic men with mcrpc - q&a
-
1:35
vision: safety analysis of 177lu-psma-617 in mcrpc
-
9:12
biweekly vs triweekly cabazitaxel & androgen receptor pathway inhibitors for mcrpc|dr. sunil chopade
-
2:23
daniel petrylak, emso 2019 - phase iii keynote-321 study in prostate cancer
-
8:28
metastatic prostate cancer: androgen receptor biology
-
1:23
the evolving treatment landscape of mhspc and mcrpc
-
4:54
molecular and clinical characterization of mcrpc patients achieving deep psa responses to bat
-
1:52
treatment sequencing in mcrpc: cabazitaxel vs. abiraterone or enzalutamide